Aspirin with acid-reducing medicine reduces chance of oesophageal cancer in high risk individuals

Bookmark and Share
Published: 4 Jun 2018
Views: 1902
Rating:
Save
Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic of Ireland

Dr Jankowski presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from the ASPECT trial.

This was a phase III randomised trial in which Barrett’s oesophagus patients at a high risk of developing high-grade dysplasia or oesophageal cancer were treated with high dose proton pump inhibitors and aspirin, and Dr Jankowski estimates that this course of treatment prevented up to a quarter of cancers developing, and delayed its development by up to 2 years in other patients.

For more on these findings, watch his interview with ecancer, or read news coverage here.

View the slides here.